Please login to bookmarkClose

A patent battle between Juno Pharmaceuticals and Bristol-Myers Squibb over the blockbuster drug Revlimid has seen both sides suffer early losses, with a judge dismissing strike out and summary dismissal applications by the drug makers.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?
Lost your password?

Contact us to enquire about group subscriptions.
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au